L-Valine Encyclopedia — Scientific Background

What Is L-Valine?

L-Valine (CAS 72-18-4), also known as (2S)-2-amino-3-methylbutanoic acid, is an essential branched-chain amino acid with the molecular formula C₅H₁₁NO₂ and a molecular weight of 117.15 g/mol. It occurs as white crystals or a crystalline powder, is odorless or has a faint characteristic odor, and has a slightly sweet taste that becomes bitter. L-Valine is freely soluble in formic acid, soluble in water (approximately 85 g/L at 20°C), and practically insoluble in ethanol and ether. L-Valine is a member of the branched-chain amino acid family, along with leucine and isoleucine, and is characterized by a branched aliphatic side chain.

Physiological Functions of L-Valine

L-Valine is an essential amino acid with several critical physiological roles:

• Muscle Protein Synthesis — L-Valine is a critical substrate for muscle protein synthesis. As a BCAA, it participates in the initiation and regulation of protein synthesis in muscle tissue, particularly under conditions of metabolic stress or injury.

• Energy Metabolism — L-Valine is a glucogenic amino acid that can be converted into glucose to support energy metabolism during fasting, intense exercise, or periods of carbohydrate restriction.

• Nitrogen Balance — L-Valine is a key nitrogen donor in the body, supporting the maintenance of nitrogen balance and the synthesis of other amino acids.

• BCAA Balance — L-Valine competes with leucine and isoleucine for transport into muscle cells via the same L-type amino acid transporter (LAT1). This competition means that an imbalance in BCAA intake can affect muscle protein synthesis. Studies have shown that ingestion of leucine alone results in a decrease in the plasma concentrations of both valine and isoleucine, and the availability of valine and isoleucine may therefore become rate limiting for muscle protein synthesis.

• Cognitive Function — L-Valine is required for smooth nervous system function and cognitive performance, and is a precursor for the synthesis of other amino acids and neurotransmitters.

Mechanisms of Action

Branched-Chain Amino Acid Metabolism

L-Valine is metabolized primarily in skeletal muscle, where it undergoes reversible transamination to α-ketoisovalerate, followed by irreversible oxidative decarboxylation to isobutyryl-CoA. This metabolic pathway generates succinyl-CoA, a TCA cycle intermediate that supports energy production and contributes to the glucogenic potential of valine. The BCAA metabolic pathway is regulated by the branched-chain α-ketoacid dehydrogenase complex (BCKDH), which determines the rate of BCAA oxidation and energy production.

Competition for Transport and BCAA Balance

L-Valine is transported into muscle cells via the L-type amino acid transporter (LAT1), which it shares with leucine and isoleucine. This shared transport system creates competition among the three BCAAs. Research has demonstrated that when leucine alone is consumed, plasma valine and isoleucine concentrations decrease, and the availability of valine and isoleucine may become rate-limiting for muscle protein synthesis. This underscores the importance of balanced BCAA supplementation and efficient delivery of each BCAA.

Glucogenic Energy Support

L-Valine is a glucogenic amino acid, meaning its carbon skeleton can be converted into glucose through gluconeogenesis. This property makes valine particularly valuable during periods of fasting, low carbohydrate intake, or high-intensity exercise, when the body requires alternative sources of glucose to sustain energy metabolism.

Nitrogen Donation and Amino Acid Synthesis

L-Valine serves as a nitrogen donor for the synthesis of other amino acids, including alanine and glutamate. This transamination function is critical for maintaining nitrogen balance and supporting the synthesis of proteins and other nitrogen-containing compounds.

The Bioavailability Challenge

Despite its essential physiological functions, native L-valine presents significant absorption challenges. Traditional crystalline amino acids rely on specific, saturable active transport systems in the brush border membrane of the small intestine. When high doses of standard BCAAs are ingested, these carrier proteins quickly become saturated, leaving a substantial portion of the amino acids unabsorbed. This unabsorbed payload is either degraded by intestinal microflora or eliminated, resulting in low systemic bioavailability. Additionally, free-form BCAAs often present poor water solubility, severe bitterness, and mucosal irritation.

Liposomal encapsulation addresses these limitations through a phospholipid bilayer that protects L-valine during digestive transit and provides an alternative absorption pathway that bypasses the competitive BCAA transporter. Liposomal L-Valine utilizes a biomimetic "Trojan Horse" delivery mechanism to circumvent these physiological barriers, delivering the amino acid directly to target tissues with optimal efficiency.

Liposomal L-Valine

Liposomal encapsulation of L-valine provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the L-valine molecule, forming a protective shell that enhances stability, absorption, and cellular uptake. This delivery system:

• Achieves >97% encapsulation efficiency with <30% cumulative release over 5 days

• Bypasses saturable intestinal transporters through lipid-mediated absorption

• Provides complete taste-masking by eliminating bitterness and mucosal irritation

• Enhances formulation stability for use in powders, capsules, and liquid sachets

Liposomal L-valine is an advanced, microencapsulated BCAA engineered for superior biological performance, enhanced formulation stability, and complete taste-masking. By applying cutting-edge biopharmaceutical-grade liposomal technology, the active L-valine molecules are enveloped within a highly stable phospholipid bilayer structure. This biomimetic matrix shields the active payload throughout digestion, delivering the amino acid directly to target tissues with optimal efficiency.

Clinical Evidence

Stability and Encapsulation Efficiency

A stability comparison study evaluated BCAA-encapsulated liposomes versus double emulsions prepared by high-speed homogenization and ultrasonication. The results demonstrated that encapsulation efficiencies of BCAA in liposomes were over 97%, with cumulative release rates below 30% for 5 days. The study confirmed that liposomal encapsulation provides excellent retention and sustained release of BCAAs, making it an ideal delivery system for these essential amino acids.

BCAA Transport and Muscle Protein Synthesis

A comprehensive review published in the Journal of the International Society of Sports Nutrition examined the relationship between BCAA supplementation and muscle protein synthesis in humans. The review noted that the BCAA metabolic pathway involves competition among leucine, valine, and isoleucine for transport into muscle cells, and that ingestion of leucine alone results in a decrease in plasma valine and isoleucine concentrations. The availability of valine and isoleucine may therefore become rate-limiting for muscle protein synthesis when leucine alone is consumed. This finding underscores the importance of balanced BCAA supplementation and efficient delivery of each BCAA, particularly valine, to support optimal muscle protein synthesis.

Safety Assessment

The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) has evaluated L-valine produced by fermentation with Corynebacterium glutamicum for use in animal nutrition and concluded that it is safe for all animal species when supplemented in appropriate amounts according to nutritional needs. Regarding user safety, the additive is not considered an irritant to skin or eyes nor a skin sensitiser, though it was considered a potential skin and respiratory sensitiser in some assessments.

Safety and Regulatory

L-Valine is generally well tolerated at commonly used doses. The Food and Nutrition Board (FNB) has recommended 24 mg/kg body weight per day for adults, which equates to 1,680 mg per day for a 70 kg adult. For children, standard prescription is 20–120 mg/kg/day added to daily enteral formula. L-Valine is a naturally occurring amino acid and is considered safe when consumed as part of a normal diet or as a dietary supplement at recommended doses.

Regulatory status varies by region:

• United States — L-Valine is regulated as a dietary supplement ingredient and is Generally Recognized As Safe (GRAS) for use in food and dietary supplements. It is monographed in the USP with an assay specification of 98.5%–101.5% on dried basis.

• European Union — L-Valine is authorized for use in food and feed in EU member states. The EFSA has evaluated L-valine produced by fermentation with Corynebacterium glutamicum and concluded that it is safe for use.

• Japan — L-Valine is monographed in the Japanese Pharmacopoeia (JP) with an assay specification of ≥98.5%.

• Global Standards — L-Valine is monographed in the USP, European Pharmacopoeia, Japanese Pharmacopoeia, and Food Chemicals Codex (FCC). The product meets requirements of residual solvents listed in the current JP, USP, and EP.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

89$/KG